{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:54:28Z","timestamp":1793066068068,"version":"4.5.0"},"reference-count":47,"publisher":"American Association for Cancer Research (AACR)","issue":"16","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Lysophosphatidic acid (LPA) is elevated in ascites of ovarian cancer patients and stimulates growth and other activities of ovarian cancer cells in vitro. Tissue hypoxia is a critical factor for tumor aggressiveness and metastasis in cancers. We tested whether the ascites of ovarian cancer is hypoxic and whether hypoxia influences the effects of LPA on ovarian cancer cells. We found that ovarian ascitic fluids were hypoxic in vivo. Enhanced cellular responsiveness to LPA, including migration and\/or invasion of ovarian cancer cells, was observed under hypoxic conditions. This enhancement could be completely blocked by geldanamycin or a small interfering RNA targeting hypoxia-inducible factor 1\u03b1 (HIF1\u03b1). LPA-induced cell migration required cytosolic phospholipase A2 (cPLA2) and LPA stimulates cPLA2 phosphorylation in a HIF1\u03b1-dependent manner under hypoxia conditions. Furthermore, we show for the first time that exogenous LPA enhances tumor metastasis in an orthotopic ovarian cancer model and HIF\u03b1 expression in tumors. 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (an inhibitor of the heat shock protein 90) effectively blocked LPA-induced tumor metastasis in vivo. Together, our data indicate that hypoxic conditions are likely to be pathologically important for ovarian cancer development. HIF1\u03b1 plays a critical role in enhancing and\/or sensitizing the role of LPA on cell migration and invasion under hypoxic conditions, where cPLA2 is required for LPA-induced cell migration. (Cancer Res 2006; 66(16): 7983-90)<\/jats:p>","DOI":"10.1158\/0008-5472.can-05-4381","type":"journal-article","created":{"date-parts":[[2006,8,15]],"date-time":"2006-08-15T17:20:57Z","timestamp":1155662457000},"page":"7983-7990","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":132,"title":["Hypoxia Enhances Lysophosphatidic Acid Responsiveness in Ovarian Cancer Cells and Lysophosphatidic Acid Induces Ovarian Tumor Metastasis <i>In vivo<\/i>"],"prefix":"10.1158","volume":"66","author":[{"given":"Kwan-Sik","family":"Kim","sequence":"first","affiliation":[{"name":"1Department of Cancer Biology, Lerner Research Institute, and"},{"name":"3Department of Obstetrics and Gynecology, Research Institute of Clinic Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saubhik","family":"Sengupta","sequence":"additional","affiliation":[{"name":"1Department of Cancer Biology, Lerner Research Institute, and"},{"name":"2Department of Obstetrics and Gynecology, Gynecological Oncology Section, Cleveland Clinic, Cleveland, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Berk","sequence":"additional","affiliation":[{"name":"1Department of Cancer Biology, Lerner Research Institute, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Geun","family":"Kwak","sequence":"additional","affiliation":[{"name":"4Department of Pharmacology, Chonbuk National University Medical School, Chonju, Chonbuk, Korea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro F.","family":"Escobar","sequence":"additional","affiliation":[{"name":"2Department of Obstetrics and Gynecology, Gynecological Oncology Section, Cleveland Clinic, Cleveland, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Belinson","sequence":"additional","affiliation":[{"name":"2Department of Obstetrics and Gynecology, Gynecological Oncology Section, Cleveland Clinic, Cleveland, Ohio;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel C.","family":"Mok","sequence":"additional","affiliation":[{"name":"5Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Boston, Massachusetts; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[{"name":"1Department of Cancer Biology, Lerner Research Institute, and"},{"name":"2Department of Obstetrics and Gynecology, Gynecological Oncology Section, Cleveland Clinic, Cleveland, Ohio;"},{"name":"6Department of Obstetrics and Gynecology, Indiana University, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2006,8,15]]},"reference":[{"key":"2022061622121902300_B1","doi-asserted-by":"crossref","unstructured":"Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin\u20082004; 54: 8\u201329.","DOI":"10.3322\/canjclin.54.1.8"},{"key":"2022061622121902300_B2","doi-asserted-by":"crossref","unstructured":"Kohn EC, Mills GB, Liotta L. Promising directions for the diagnosis and management of gynecological cancers. Int J Gynaecol Obstet\u20082003; 83 Suppl 1: 203\u20139.","DOI":"10.1016\/S0020-7292(03)90122-6"},{"key":"2022061622121902300_B3","doi-asserted-by":"crossref","unstructured":"Mills GB, Fang X, Lu Y, et al. Specific keynote: molecular therapeutics in ovarian cancer. Gynecol Oncol\u20082003; 88: S88\u201392;discussion S93\u201386.","DOI":"10.1006\/gyno.2002.6692"},{"key":"2022061622121902300_B4","doi-asserted-by":"crossref","unstructured":"Karlan BY, Krakow D. Genetic aspects of ovarian cancer. Curr Opin Obstet Gynecol\u20081994; 6: 105\u201310.","DOI":"10.1097\/00001703-199402000-00017"},{"key":"2022061622121902300_B5","doi-asserted-by":"crossref","unstructured":"Berchuck A, Elbendary A, Havrilesky L, Rodriguez GC, Bast RC, Jr. Pathogenesis of ovarian cancers. J Soc Gynecol Investig\u20081994; 1: 181\u201390.","DOI":"10.1177\/107155769400100302"},{"key":"2022061622121902300_B6","doi-asserted-by":"crossref","unstructured":"Pickel H, Lahousen M, Stettner H, Girardi F. The spread of ovarian cancer. Baillieres Clin Obstet Gynaecol\u20081989; 3: 3\u201312.","DOI":"10.1016\/S0950-3552(89)80036-7"},{"key":"2022061622121902300_B7","doi-asserted-by":"crossref","unstructured":"Gardner MJ, Jones LM, Catterall JB, Turner GA. Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis. Cancer Lett\u20081995; 91: 229\u201334.","DOI":"10.1016\/0304-3835(95)03743-G"},{"key":"2022061622121902300_B8","doi-asserted-by":"crossref","unstructured":"Xu Y, Fang XJ, Casey G, Mills GB. Lysophospholipids activate ovarian and breast cancer cells. Biochem J\u20081995; 309: 933\u201340.","DOI":"10.1042\/bj3090933"},{"key":"2022061622121902300_B9","unstructured":"Xu Y, Gaudette DC, Boynton JD, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res\u20081995; 1: 1223\u201332."},{"key":"2022061622121902300_B10","doi-asserted-by":"crossref","unstructured":"Xu Y, Xiao YJ, Zhu K, et al. Unfolding the pathophysiological role of bioactive lysophospholipids. Curr Drug Targets Immune Endocr Metabol Disord\u20082003; 3: 23\u201332.","DOI":"10.2174\/1568008033340414"},{"key":"2022061622121902300_B11","doi-asserted-by":"crossref","unstructured":"Sengupta S, Wang Z, Tipps R, Xu Y. Biology of LPA in health and disease. Semin Cell Dev Biol\u20082004; 15: 503\u201312.","DOI":"10.1016\/j.semcdb.2004.05.003"},{"key":"2022061622121902300_B12","doi-asserted-by":"crossref","unstructured":"Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer\u20082003; 3: 582\u201391.","DOI":"10.1038\/nrc1143"},{"key":"2022061622121902300_B13","doi-asserted-by":"crossref","unstructured":"Huang MC, Lee HY, Yeh CC, Kong Y, Zaloudek CJ, Goetzl EJ. Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA2). Oncogene\u20082004; 23: 122\u20139.","DOI":"10.1038\/sj.onc.1206986"},{"key":"2022061622121902300_B14","doi-asserted-by":"crossref","unstructured":"Sengupta S, Xiao YJ, Xu Y. A novel laminin-induced LPA autocrine loop in the migration of ovarian cancer cells. FASEB J\u20082003; 17: 1570\u20132.","DOI":"10.1096\/fj.02-1145fje"},{"key":"2022061622121902300_B15","doi-asserted-by":"crossref","unstructured":"Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer\u20082002; 2: 38\u201347.","DOI":"10.1038\/nrc704"},{"key":"2022061622121902300_B16","doi-asserted-by":"crossref","unstructured":"Quintero M, Mackenzie N, Brennan PA. Hypoxia-inducible factor 1 (HIF-1) in cancer. Eur J Surg Oncol\u20082004; 30: 465\u20138.","DOI":"10.1016\/j.ejso.2004.03.008"},{"key":"2022061622121902300_B17","doi-asserted-by":"crossref","unstructured":"Brown MR, Blanchette JO, Kohn EC. Angiogenesis in ovarian cancer. Baillieres Best Pract Res Clin Obstet Gynaecol\u20082000; 14: 901\u201318.","DOI":"10.1053\/beog.2000.0134"},{"key":"2022061622121902300_B18","doi-asserted-by":"crossref","unstructured":"Chambers SK, Gertz RE, Jr., Ivins CM, Kacinski BM. The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer. Cancer\u20081995; 75: 1627\u201333.","DOI":"10.1002\/1097-0142(19950401)75:7<1627::AID-CNCR2820750712>3.0.CO;2-V"},{"key":"2022061622121902300_B19","doi-asserted-by":"crossref","unstructured":"Schwartz BM, Hong G, Morrison BH, et al. Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. Gynecol Oncol\u20082001; 81: 291\u2013300.","DOI":"10.1006\/gyno.2001.6124"},{"key":"2022061622121902300_B20","doi-asserted-by":"crossref","unstructured":"Hu YL, Tee MK, Goetzl EJ, et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst\u20082001; 93: 762\u20138.","DOI":"10.1093\/jnci\/93.10.762"},{"key":"2022061622121902300_B21","unstructured":"Pustilnik TB, Estrella V, Wiener JR, et al. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res\u20081999; 5: 3704\u201310."},{"key":"2022061622121902300_B22","doi-asserted-by":"crossref","unstructured":"Fang X, Yu S, Bast RC, et al. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem\u20082004; 279: 9653\u201361.","DOI":"10.1074\/jbc.M306662200"},{"key":"2022061622121902300_B23","unstructured":"Repesh LA. A new in vitro assay for quantitating tumor cell invasion. Invasion Metastasis\u20081989; 9: 192\u2013208."},{"key":"2022061622121902300_B24","doi-asserted-by":"crossref","unstructured":"Lu J, Xiao YJ, Baudhuin LM, Hong G, Xu Y. Role of ether-linked lysophosphatidic acids in ovarian cancer cells. J Lipid Res\u20082002; 43: 463\u201376.","DOI":"10.1016\/S0022-2275(20)30153-X"},{"key":"2022061622121902300_B25","doi-asserted-by":"crossref","unstructured":"Ren J, Xiao XJ, Singh LS, et al. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration and invasion of ovarian cancer cells. Cancer Res\u20082006; 66: 3006\u201314.","DOI":"10.1158\/0008-5472.CAN-05-1292"},{"key":"2022061622121902300_B26","unstructured":"Mabjeesh NJ, Post DE, Willard MT, et al. Geldanamycin induces degradation of hypoxia-inducible factor 1\u03b1 protein via the proteosome pathway in prostate cancer cells. Cancer Res\u20082002; 62: 2478\u201382."},{"key":"2022061622121902300_B27","doi-asserted-by":"crossref","unstructured":"Nguyen DM, Desai S, Chen A, Weiser TS, Schrump DS. Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin. Ann Thorac Surg\u20082000; 70: 1853\u201360.","DOI":"10.1016\/S0003-4975(00)01810-5"},{"key":"2022061622121902300_B28","unstructured":"Vasilevskaya IA, O'Dwyer PJ. Effects of geldanamycin on signaling through activator-protein 1 in hypoxic HT29 human colon adenocarcinoma cells. Cancer Res\u20081999; 59: 3935\u201340."},{"key":"2022061622121902300_B29","unstructured":"Piccinno R, Puopolo M, Rigault De La Longrais IA, Fracchioli S, Massobrio M, Katsaros D. Growth factors in epithelial ovarian cancer. Minerva Ginecol\u20082002; 54: 33\u201352."},{"key":"2022061622121902300_B30","doi-asserted-by":"crossref","unstructured":"Xiao YJ, Schwartz B, Washington M, et al. Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem\u20082001; 290: 302\u201313.","DOI":"10.1006\/abio.2001.5000"},{"key":"2022061622121902300_B31","doi-asserted-by":"crossref","unstructured":"Xiao Y, Chen Y, Kennedy AW, Belinson J, Xu Y. Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses. Ann N Y Acad Sci\u20082000; 905: 242\u201359.","DOI":"10.1111\/j.1749-6632.2000.tb06554.x"},{"key":"2022061622121902300_B32","unstructured":"Kiguchi K, Kubota T, Aoki D, et al. A patient-like orthotopic implantation nude mouse model of highly metastatic human ovarian cancer. Clin Exp Metastasis\u20081998; 16: 751\u20136."},{"key":"2022061622121902300_B33","unstructured":"Eder AM, Sasagawa T, Mao M, Aoki J, Mills GB. Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res\u20082000; 6: 2482\u201391."},{"key":"2022061622121902300_B34","doi-asserted-by":"crossref","unstructured":"Xu Y, Xiao YJ, Baudhuin LM, Schwartz BM. The role and clinical applications of bioactive lysolipids in ovarian cancer. J Soc Gynecol Investig\u20082001; 8: 1\u201313.","DOI":"10.1177\/107155760100800101"},{"key":"2022061622121902300_B35","doi-asserted-by":"crossref","unstructured":"Massazza G, Tomasini A, Lucchini V, et al. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. Int J Cancer\u20081989; 44: 494\u2013500.","DOI":"10.1002\/ijc.2910440320"},{"key":"2022061622121902300_B36","unstructured":"Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res\u20082000; 6: 880\u20136."},{"key":"2022061622121902300_B37","doi-asserted-by":"crossref","unstructured":"Hollingshead M, Alley M, Burger AM, et al. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol\u20082005; 56: 115\u201325.","DOI":"10.1007\/s00280-004-0939-2"},{"key":"2022061622121902300_B38","doi-asserted-by":"crossref","unstructured":"Knisely JP, Rockwell S. Importance of hypoxia in the biology and treatment of brain tumors. Neuroimaging Clin N Am\u20082002; 12: 525\u201336.","DOI":"10.1016\/S1052-5149(02)00032-1"},{"key":"2022061622121902300_B39","doi-asserted-by":"crossref","unstructured":"Baker DL, Morrison P, Miller B, et al. Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA\u20082002; 287: 3081\u20132.","DOI":"10.1001\/jama.287.23.3081"},{"key":"2022061622121902300_B40","doi-asserted-by":"crossref","unstructured":"Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer\u20082003; 3: 721\u201332.","DOI":"10.1038\/nrc1187"},{"key":"2022061622121902300_B41","doi-asserted-by":"crossref","unstructured":"Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature\u20082003; 425: 407\u201310.","DOI":"10.1038\/nature01913"},{"key":"2022061622121902300_B42","doi-asserted-by":"crossref","unstructured":"Murakami M. Hot topics in phospholipase A2 field. Biol Pharm Bull\u20082004; 27: 1179\u201382.","DOI":"10.1248\/bpb.27.1179"},{"key":"2022061622121902300_B43","doi-asserted-by":"crossref","unstructured":"Sa G, Murugesan G, Jaye M, Ivashchenko Y, Fox PL. Activation of cytosolic phospholipase A2 by basic fibroblast growth factor via a p42 mitogen-activated protein kinase-dependent phosphorylation pathway in endothelial cells. J Biol Chem\u20081995; 270: 2360\u20136.","DOI":"10.1074\/jbc.270.5.2360"},{"key":"2022061622121902300_B44","doi-asserted-by":"crossref","unstructured":"Bernatchez PN, Tremblay F, Rollin S, Neagoe PE, Sirois MG. Sphingosine 1-phosphate effect on endothelial cell PAF synthesis: role in cellular migration. J Cell Biochem\u20082003; 90: 719\u201331.","DOI":"10.1002\/jcb.10686"},{"key":"2022061622121902300_B45","doi-asserted-by":"crossref","unstructured":"Lesur O, Bernard A, Arsalane K, et al. Clara cell protein (CC-16) induces a phospholipase A2-mediated inhibition of fibroblast migration in vitro. Am J Respir Crit Care Med\u20081995; 152: 290\u20137.","DOI":"10.1164\/ajrccm.152.1.7541278"},{"key":"2022061622121902300_B46","doi-asserted-by":"crossref","unstructured":"Kalyankrishna S, Malik KU. Norepinephrine-induced stimulation of p38 mitogen-activated protein kinase is mediated by arachidonic acid metabolites generated by activation of cytosolic phospholipase A(2) in vascular smooth muscle cells. J Pharmacol Exp Ther\u20082003; 304: 761\u201372.","DOI":"10.1124\/jpet.102.040949"},{"key":"2022061622121902300_B47","doi-asserted-by":"crossref","unstructured":"Dronadula N, Liu Z, Wang C, Cao H, Rao GN. STAT-3-dependent cytosolic phospholipase A2 expression is required for thrombin-induced vascular smooth muscle cell motility. J Biol Chem\u20082005; 280: 3112\u201320.","DOI":"10.1074\/jbc.M409739200"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/16\/7983\/2551593\/7983.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/16\/7983\/2551593\/7983.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:12:30Z","timestamp":1655424750000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/66\/16\/7983\/525941\/Hypoxia-Enhances-Lysophosphatidic-Acid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,15]]},"references-count":47,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2006,8,15]]},"published-print":{"date-parts":[[2006,8,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-05-4381","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,15]]}}}